Fundraising Fox

Evox Therapeutics

Founded 2016 · 36 employees on LinkedIn · 6 known investors

Find your way into Evox Therapeutics

Evox Therapeutics develops exosome-based gene editing therapies using its ExoEdit platform, which combines exosome delivery with a proprietary CRISPR-based editor to treat severe neurodegenerative and other genetically-driven diseases. The therapies target the central nervous system to address the root cause of neurodegeneration.

BiotechDeep Tech

Investors · 6

OrbiMedNew York · $1M – $75M
Oxford Science EnterprisesOxford · $63.5K – $31.8M
Panacea VentureSingapore
Cowen Healthcare InvestmentsreportedNew York
GV (Google Ventures)reportedMountain View · $250K – $50M
REDMILEreportedSan Francisco

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Top 4 Most Richly Funded Exosome Startups in the Worldbioinformant.com · Sep 2024Evox Therapeutics Closes £69.2M Series C Financing - FinSMEsfinsmes.com · Feb 2021Evox Therapeutics Secures £1.5M in Funding from Innovate UKfinsmes.com · Mar 2019Evox Therapeutics raises $45 million for exosome therapiescen.acs.org · Sep 2018Evox Therapeutics raises new funds to support drug developmentpharmaceutical-technology.com · Sep 2018Evox Therapeutics Raises €40M to Deliver Drugs to Hard-to-Reach Targetslabiotech.eu · Sep 2018

Frequently asked questions

What does Evox Therapeutics do?
Evox Therapeutics develops exosome-based gene editing therapies using its ExoEdit platform, which combines exosome delivery with a proprietary CRISPR-based editor to treat severe neurodegenerative and other genetically-driven diseases. The therapies target the central nervous system to address the root cause of neurodegeneration.
Who are Evox Therapeutics's investors?
Evox Therapeutics's investors include OrbiMed, Oxford Science Enterprises, Panacea Venture, Cowen Healthcare Investments, GV (Google Ventures), REDMILE.